Cell Free DNA; Research; Patient Care

Panel Debate: Cell Free DNA
CME (AMA PRA Category 1 Credits™) 0.75; ACPE (UAN: 0853-9999-17-064-L01-P) 0.75; CEU (NSGC Category 1) 0.075; Attendance CEU 0.75

Tuesday, October 10
4:00 PM - 4:45 PM

Learning Objectives:

Minetta C. Liu

Associate Professor of Oncology
Mayo Clinic

Minetta C. Liu, MD, is a consultant in the Department of Oncology at Mayo Clinic Minnesota. She serves as Research Chair for the Division of Medical Oncology; co-chair of the Breast Cancer Pathology Disease Oriented Group; and leader of the Circulating Tumor Cell and Cell Free DNA Working Group. She is also the Medical Director for Specialty Contract Operations and an Associate Medical Director in the Department of Development.

Dr. Liu earned her M.D. at Jefferson Medical College in Philadelphia, Pennsylvania. She completed her internal medicine residency and hematology/oncology fellowship at Georgetown University Medical Center in Washington, D.C.

As a physician and translational researcher, Dr. Liu specializes in breast medical oncology and clinical and laboratory-based cancer research. She is dedicated to improving patient outcomes through access to novel therapeutic agents and molecular diagnostic tools. Her laboratory efforts focus on expanding the clinical applications of circulating nucleic acid and circulating tumor cell assays for solid tumor malignancies. Her funding sources include the National Cancer Institute, Department of Defense, Breast Cancer Research Foundation, and Susan G. Komen for the Cure. She has co-authored numerous articles that have been published in peer-reviewed journals, and she holds editorial board member and reviewer responsibilities for prominent scientific publications.

In recognition of her work, Dr. Liu has received teaching awards and is listed as an honored member in America’s Registry of Outstanding Professionals and Marquis’ Who’s Who in Medicine and Healthcare.

Dr. Liu’s memberships in professional organizations include the Evelyn H. Lauder Founder’s Fund Collaboration (co-chair, Clinical Working Group); the Alliance for Clinical Trials in Oncology (member, Translational Research Program Executive Committee); the Translational Breast Cancer Research Consortium (co-chair, Correlative Science Working Group); and the Academic and Community Cancer Research United (member, Board of Directors).

Presentation(s):

Send Email for Minetta Liu

Muhammed Murtaza

Assistant Professor of Medicine
Mayo Clinic

Muhammed Murtaza, MBBS, PhD, is an Assistant Professor and Co-Director of the Center for Noninvasive Diagnostics at TGen, a non-profit research institute in Phoenix, AZ and jointly appointed at Mayo Clinic in Arizona. His group focuses on development of novel methods and applications for circulating tumor DNA analysis in cancer patients. Murtaza has published groundbreaking studies describing sequencing of circulating tumor DNA for tracking cancer burden and evolution. Prior to his current position, he received a PhD from the University of Cambridge and an MBBS (MD) from Aga Khan University in Pakistan.

Presentation(s):

Send Email for Muhammed Murtaza

Richard Williams

Medical Director at GRAIL, Inc
GRAIL

Richard T. Williams, MBBS, PhD, is Group Medical Director at GRAIL, a life sciences company whose mission is to detect cancer early when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical trials, and state of the art Computer Science and Data Science to enhance the scientific understanding of cancer biology and develop blood tests for early-stage cancer detection.

Dr Williams serves as Project Lead for GRAIL's Circulating Cell-Free Genome Atlas (CCGA) Study, which will characterize the landscape of cell-free DNA profiles in several thousand individuals with cancer and in thousands of healthy non-cancer participants using GRAIL's "high-intensity" (ultra-broad and ultra-deep) sequencing approach.

Dr Williams earned both his medical degree (MBBS) and PhD degrees at the University of Queensland, Australia and undertook pediatric residency training at the Royal Children's Hospital, Melbourne, Australia. He then completed his pediatric hematology & oncology fellowship and further laboratory training at St Jude Children's Research Hospital, where he later established and led an independent translational cancer genetics laboratory. Over the last several years, he has held positions of increasing responsibility for oncology therapeutic programs in Amgen's Global Development function, at Puma Biotechnology, and as Head of Early Development Oncology at Amgen.

Dr Williams has co-authored 58 articles that have been published in peer-reviewed journals, and is co-inventor on 1 patent, and is a member of ASCO, AACR, ASH.



Presentation(s):

Send Email for Richard Williams


Assets

Panel Debate: Cell Free DNA
CME (AMA PRA Category 1 Credits™) 0.75; ACPE (UAN: 0853-9999-17-064-L01-P) 0.75; CEU (NSGC Category 1) 0.075; Attendance CEU 0.75



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Panel Debate: Cell Free DNA
CME (AMA PRA Category 1 Credits™) 0.75; ACPE (UAN: 0853-9999-17-064-L01-P) 0.75; CEU (NSGC Category 1) 0.075; Attendance CEU 0.75